Why Eli Lilly Stock Sank 18% This Week

05:25pm, Friday, 08'th Aug 2025
Shares of Eli Lilly (LLY -2.37%) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker with a market cap of over $500 billion is in a sharp drawdown due to previousl
The Investment Committee debate the latest Calls of the Day and how to trade them.
Industry pioneer Novo Nordisk A/S NYSE: NVO saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly NYSE: LLY shares fell approximately 14%.
LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization

Eli Lilly: 50% Upside For LLY Stock?

09:55am, Friday, 08'th Aug 2025
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This pos
Eli Lilly (LLY -14.23%) stock is down big this year. It has lost 17% of its value thus far in 2025 (returns as of Aug. 7).
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti
Major U.S. equities indexes were mixed Thursday after the overnight onset of President Trump's "reciprocal" tariffs, which increased the levies imposed on imports from a broad range of trading partner
Evan Seigerman, BMO, joins 'Fast Money' to talk the latest oral obesity treatment data out of Eli Lilly.
"This market is priced for perfection," says Rebecca Walser (@walserwealth) and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used f
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall St

Why Eli Lilly Stock Is Plunging Today

01:53pm, Thursday, 07'th Aug 2025
Shares of Eli Lilly (LLY -14.29%) were plunging 14.8% as of 11:14 a.m. ET on Thursday.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE